These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 21085773)

  • 21. The rise and fall of rosiglitazone: reply.
    Slaoui M
    Eur Heart J; 2010 May; 31(10):1282-4. PubMed ID: 20499440
    [No Abstract]   [Full Text] [Related]  

  • 22. Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate.
    Venero CV; Thompson PD; Fernandez AB
    Am J Med; 2008 Oct; 121(10):e3-4. PubMed ID: 18823843
    [No Abstract]   [Full Text] [Related]  

  • 23. No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
    Perségol L; Duvillard L; Monier S; Brindisi MC; Bouillet B; Petit JM; Vergès B
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E2015-9. PubMed ID: 25137425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic injury in a patient taking rosiglitazone.
    Menees SB; Anderson MA; Chensue SW; Moseley RH
    J Clin Gastroenterol; 2005 Aug; 39(7):638-40. PubMed ID: 16000935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated creatine kinase and myalgia in a patient taking rosiglitazone.
    Kennie N; Antoniou T; Berger P
    Ann Pharmacother; 2007 Mar; 41(3):521-4. PubMed ID: 17327290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
    Lebovitz HE; Kreider M; Freed MI
    Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-generation thiazolidinediones and hepatotoxicity.
    Marcy TR; Britton ML; Blevins SM
    Ann Pharmacother; 2004 Sep; 38(9):1419-23. PubMed ID: 15266041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mild, reversible pancytopenia induced by rosiglitazone.
    Maaravi Y; Stessman J
    Diabetes Care; 2005 Jun; 28(6):1536. PubMed ID: 15920093
    [No Abstract]   [Full Text] [Related]  

  • 30. Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus.
    Cekmen N; Cesur M; Cetinbas R; Bedel P; Erdemli O
    J Intensive Care Med; 2006; 21(1):47-50. PubMed ID: 16698744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes.
    van Wijk JP; de Koning EJ; Castro Cabezas M; Rabelink TJ
    Diabetes Care; 2005 Apr; 28(4):844-9. PubMed ID: 15793183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.
    Vilar L; Canadas V; Arruda MJ; Arahata C; Agra R; Pontes L; Montenegro L; Vilar CF; Silva LM; Albuquerque JL; Gusmão A
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(3):311-8. PubMed ID: 20520962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.
    Shargorodsky M; Michaelova K; Boaz M; Gavish D; Zimlichman R
    Diabet Med; 2007 Nov; 24(11):1254-60. PubMed ID: 17725634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
    Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
    Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

  • 37. Leukopenia and thrombocytopenia caused by thiazolidinediones.
    Digman C; Klein AK; Pittas AG
    Ann Intern Med; 2005 Sep; 143(6):465-6. PubMed ID: 16172449
    [No Abstract]   [Full Text] [Related]  

  • 38. [Macular oedema due to rosiglitazone treatment in diabetes mellitus].
    Asensio-Sánchez VM; Asensio-Sánchez MJ; Gómez-Ramírez V
    Arch Soc Esp Oftalmol; 2010 Jul; 85(7):246-8. PubMed ID: 21093714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
    Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
    Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ
    Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.